Christopher W Lee
Overview
Explore the profile of Christopher W Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
876
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Assmann N, Rameckers S, Schaich A, Lee C, Boterhoven de Haan K, Rijkeboer M, et al.
Eur J Psychotraumatol
. 2024 Sep;
15(1):2397890.
PMID: 39263714
The relationship between trauma-related negative cognitions and post-traumatic stress disorder (PTSD) symptoms has been studied frequently. Several studies found a mediating effect of trauma-related negative cognitions on symptom reduction in...
2.
Piccirillo M, Chu Q, Bradbury P, Tu W, Coschi C, Grosso F, et al.
J Thorac Oncol
. 2024 Aug;
19(11):1578-1579.
PMID: 39186030
No abstract available.
3.
Rameckers S, van Emmerik A, Boterhoven de Haan K, Kousemaker M, Fassbinder E, Lee C, et al.
Behav Res Ther
. 2024 Feb;
175:104492.
PMID: 38359658
We studied the mechanisms of eye movement desensitization and reprocessing (EMDR) and imagery rescripting (ImRs). We hypothesized that EMDR works via changes in memory vividness, that ImRs works via changes...
4.
Chu Q, Perrone F, Greillier L, Tu W, Piccirillo M, Grosso F, et al.
Lancet
. 2023 Nov;
402(10419):2295-2306.
PMID: 37931632
Background: Pleural mesothelioma usually presents at an advanced, incurable stage. Chemotherapy with platinum-pemetrexed is a standard treatment. We hypothesised that the addition of pembrolizumab to platinum-pemetrexed would improve overall survival...
5.
Kuck S, Arntz A, Rameckers S, Lee C, Boterhoven de Haan K, Fassbinder E, et al.
Clin Psychol Psychother
. 2023 Apr;
30(5):1029-1046.
PMID: 37078854
Sudden gains, defined as large and stable improvements in symptom severity during psychological treatment, have consistently been found to be associated with better outcomes across treatments and diagnoses. Yet, insights...
6.
Piccirillo M, Chu Q, Bradbury P, Tu W, Coschi C, Grosso F, et al.
J Thorac Oncol
. 2023 Feb;
18(6):813-819.
PMID: 36841541
Immune checkpoint inhibitors have activity in mesothelioma. IND.227 was a phase 2 trial (120 patients planned) comparing progression-free survival of standard platinum and pemetrexed (CP) versus CP + pembrolizumab (pembro)...
7.
Speltz T, Qiao Z, Swenson C, Shangguan X, Coukos J, Lee C, et al.
Nat Biotechnol
. 2022 Oct;
41(4):541-551.
PMID: 36302987
Despite unequivocal roles in disease, transcription factors (TFs) remain largely untapped as pharmacologic targets due to the challenges in targeting protein-protein and protein-DNA interactions. Here we report a chemical strategy...
8.
Wheatley-Price P, Moore S, Lee C
JTO Clin Res Rep
. 2022 May;
3(4):100300.
PMID: 35510132
No abstract available.
9.
Wetzelaer P, Farrell J, Evers S, Jacob G, Lee C, Brand O, et al.
BMC Psychiatry
. 2022 Mar;
22(1):216.
PMID: 35337286
No abstract available.
10.
Arntz A, Jacob G, Lee C, Brand-de Wilde O, Fassbinder E, Harper R, et al.
JAMA Psychiatry
. 2022 Mar;
79(4):287-299.
PMID: 35234828
Importance: Schema therapy (ST), delivered either in an individual or group format, has been compared with other active treatments for borderline personality disorder (BPD). To our knowledge, the 2 formats...